Full Press Release Details
Cellectar Biosciences
Reports Financial Results for Q2 2024 and Provides a Corporate Update
host a conference call today at 8:30 am ET
August 13, 2024 - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery,
development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended June
30, 2024, and provided a corporate update.
recent positive data announcement from the CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom's macroglobulinemia,
we remain focused on filing our WM NDA in the fourth quarter of this year," said James Caruso, president and CEO of Cellectar.
"We anticipate an accelerated six-month NDA review period and continue to prepare for a potential launch of iopofosine in 2025.
We look forward to bringing this meaningful therapy to market and establishing iopofosine I 131 as the standard of care for the treatment
of relapsed and refractory WM patients."
and Recent Corporate Highlights
2024 Financial Highlights
Conference Call & Webcast Details
Cellectar management
will host a conference call for investors today, August 13, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer
questions. Stockholders and other interested parties may participate in the conference call by dialing 1-800-717-1738. The call will
be available via webcast by clicking HERE or on the Events page of the company's website.
Cellectar Biosciences, Inc.
Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the
treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage
its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments,
delivering improved efficacy and better safety as a result of fewer off-target effects.
company's product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of
iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
more information, please visit www.cellectar.com or join the conversation by liking and following us on the company's
social media channels: Twitter, LinkedIn, and Facebook.
Statement Disclaimer
news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect,"
"believe," "anticipate," "intend," "could," "estimate," "continue," "plans,"
or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ materially from the statements made. These statements are based on our
current beliefs and expectations as to such future outcomes including our expectations regarding the CLOVER WaM pivotal trial. Drug discovery
and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine,
the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development
thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability
to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical
collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product
pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our
periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2023, and
our Form 10-Q for the quarter ended March 31, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim
any obligation to update any such forward-looking statements.
Chief Financial Officer